Oncotelic: Pioneering Transformative Medical Breakthroughs
“Oncotelic's mission is to pioneer the development of first-in-class antisense therapies focused on TGF beta-2, a new frontier in treatment possibilities”, explains Dr. Anthony E. Maida, III, Ph.D., MA, MBA, BA, BA Chief Clinical Officer – Translational Medicine, of Oncotelic.
By strategically targeting TGF beta-2 molecules through RNA-based technology, Oncotelic seeks to explore the treatment possibilities, promising hope to patients facing daunting medical challenges.
Oncotelic’s notable progress includes two standout therapies—OT 101, a first-in-class antisense-focused therapy targeting TGF beta-2; and the CA4P drug, which has garnered significant attention for potential use in triple-negative breast cancer. It has shown promising single-agent activity in clinical trials for hard-to-treat cancer patients. These treatments exemplify Oncotelic's commitment to transforming cancer treatment and other therapeutic areas, attracting interest from key opinion leaders, centers of excellence, and major pharmaceutical firms.
Expanding its focus beyond cancer therapy, Oncotelic investigates the potential of TGF beta2, in treating infectious diseases like SARS-COVID-19.
Its diverse functions in cellular processes, like proliferation, vascularization, and fibrosis, make it a promising target for a broad range of indications showcasing its potential for diverse therapeutic applications.
Oncotelic's phase 2 trials have shown positive results for glioblastoma, melanoma, and pancreatic cancer, both as standalone treatments and in combination with chemotherapy.
The challenge of expeditiously transitioning to phase three clinical trials, while maintaining safety standards, is addressed by Oncotelic's proactive approach of interdisciplinary and investigator-initiated studies. Partnerships with key opinion leaders, major pharmaceutical firms, and centers of excellence aid in streamlining the research process, facilitating faster clinical trials. It also successfully partnered with several major pharmaceutical firms and various centers of excellence, gaining access to additional resources, knowledge, and infrastructure. It enables the company to accelerate clinical trial processes, leverage existing capabilities, and optimize its approach.
Simultaneously, Oncotelic has initiated six clinical trials aimed at generating robust data, validating phase 3 trial progression, and potentially leading to successful registration or licensure. Oncotelic’s primary focus is on developing enhanced response rates through combination therapies. Although the trials are in their early stages and the data is pending, it diligently conducts pre- and post-therapeutic biopsies, along with recurrent biopsies, to assess all crucial factors.
To fully evaluate its treatments, Oncotelic studies around 770 genes, analyzing the spatial distribution of immune cells, and identifying phenotypic changes across different treatment phases. Oncotelic also investigates various aspects, such as MDSC (Myeloid-Derived Suppressor Cells), cytokines, TT regulatory cells, CD4, CD8, cold tumors, and hot tumors. The depth of its research allows for a rigorous assessment of the tumor microenvironment.
Prioritizing rare pediatric cancers, Oncotelic applies its drug development expertise to improve treatment outcomes and survival rates for young patients with complex medical conditions.
Led by a highly skilled and agile team of experts, Oncotelic leverages collaborations and advanced technologies to establish itself as a prominent entity in revolutionizing cancer treatment and other therapeutic domains. As a leader in innovative immunotherapeutics, Oncotelic seeks to pioneer groundbreaking therapies.
Oncotelic's phase 2 trials have shown positive results for glioblastoma, melanoma, and pancreatic cancer, both as standalone treatments and in combination with chemotherapy.
The challenge of expeditiously transitioning to phase three clinical trials, while maintaining safety standards, is addressed by Oncotelic's proactive approach of interdisciplinary and investigator-initiated studies. Partnerships with key opinion leaders, major pharmaceutical firms, and centers of excellence aid in streamlining the research process, facilitating faster clinical trials. It also successfully partnered with several major pharmaceutical firms and various centers of excellence, gaining access to additional resources, knowledge, and infrastructure. It enables the company to accelerate clinical trial processes, leverage existing capabilities, and optimize its approach.
Simultaneously, Oncotelic has initiated six clinical trials aimed at generating robust data, validating phase 3 trial progression, and potentially leading to successful registration or licensure. Oncotelic’s primary focus is on developing enhanced response rates through combination therapies. Although the trials are in their early stages and the data is pending, it diligently conducts pre- and post-therapeutic biopsies, along with recurrent biopsies, to assess all crucial factors.
Our mission centers around the first-in-class antisense-focused therapy for TGF beta- 2, showcasing a laser-focused dedication to unlocking a new realm of treatment possibilities
Prioritizing rare pediatric cancers, Oncotelic applies its drug development expertise to improve treatment outcomes and survival rates for young patients with complex medical conditions.
Led by a highly skilled and agile team of experts, Oncotelic leverages collaborations and advanced technologies to establish itself as a prominent entity in revolutionizing cancer treatment and other therapeutic domains. As a leader in innovative immunotherapeutics, Oncotelic seeks to pioneer groundbreaking therapies.
